A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
← catalyst calendarNCT05873686 · readout ≤ 224 d
Sponsored by Nuvectis Pharma, Inc. (industry) · NVCT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
140estimated
Sites
15
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-26 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- NSCLC (Non-small Cell Lung Cancer)
- Renal Cancer
- Mesothelioma
- Non-Small Cell Squamous Lung Cancer
- Non-small Cell Lung Adenocarcinoma
Intervention
- Drug: NXP900
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with treatment related adverse events and/or clinical laboratory abnormalities
measured Up to 30 days post treatment
Part A: Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol
measured Day 28
Part B: Objective response rate (ORR)
measured Up to 24 months
Part B: Duration of Response (DoR)
measured Up to 24 months
Part B: Disease Control Rate (DCR)
measured Up to 24 months
Publications
- PMID 39089584 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVCT's whole pipeline · Catalyst calendar · Every registered study · What changed